Lineage Cell Therapeutics, Inc. (LCTX) Gross Margin
- Gross margin · 12 months: Value (m); Formula and calculation Gross profit / revenue. Period ending 2026-06-30..
Gross margin
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Gross margin · 12 months | (m) | Gross profit / revenue. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Gross profit | (m) | Gross Profit |
| Revenue | 13.08M USD | Revenue from Contract with Customer, Excluding Assessed Tax |
| Cost of products and services | (m) |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Gross profit (USD) | Revenue (USD) | Cost of products and services (USD) | Gross margin |
|---|---|---|---|---|
| 2026-06-30 | (m) | $13.08M | (m) | (m) |
| 2026-03-31 | (m) | $14.78M | (m) | (m) |
| 2025-12-31 | (m) | $14.56M | (m) | (m) |
| 2025-09-30 | (m) | $10.82M | (m) | (m) |
| 2025-06-30 | (m) | $10.91M | (m) | (m) |
| 2025-03-31 | (m) | $9.56M | (m) | (m) |
| 2024-12-31 | (m) | $9.50M | (m) | (m) |
| 2024-09-30 | (m) | $8.72M | (m) | (m) |
| 2024-06-30 | (m) | $6.19M | (m) | (m) |
| 2024-03-31 | (m) | $8.00M | (m) | (m) |
| 2023-12-31 | $8.27M | $8.95M | (m) | 92.50% |
| 2023-09-30 | $8.26M | $8.77M | (m) | 94.11% |
| 2023-06-30 | $9.94M | $10.52M | (m) | 94.46% |
| 2023-03-31 | $11.18M | $11.85M | (m) | 94.34% |
| 2022-12-31 | $13.97M | $14.70M | (m) | 95.05% |
| 2022-09-30 | $13.13M | $13.96M | (m) | 94.05% |
| 2022-06-30 | $11.65M | $13.23M | (m) | 88.06% |
| 2022-03-31 | $7.70M | $9.19M | (m) | 83.78% |
| 2021-12-31 | $2.92M | $4.34M | (m) | 67.15% |
| 2021-09-30 | $2.19M | $3.53M | (m) | 62.13% |
| 2021-06-30 | $1.38M | $1.83M | (m) | 75.23% |
| 2021-03-31 | $1.30M | (m) | (m) | (m) |
| 2020-12-31 | $1.44M | $1.83M | (m) | 78.92% |
| 2020-09-30 | $2.32M | (m) | (m) | (m) |
| 2020-06-30 | $2.30M | (m) | (m) | (m) |
| 2020-03-31 | $2.66M | (m) | (m) | (m) |
| 2019-12-31 | $3.10M | $3.52M | (m) | 88.28% |
| 2019-09-30 | $2.69M | (m) | (m) | (m) |
| 2019-06-30 | $3.19M | (m) | (m) | (m) |
| 2019-03-31 | $4.95M | (m) | (m) | (m) |
| 2018-12-31 | $4.69M | $4.99M | (m) | 93.95% |
| 2018-09-30 | $4.92M | $5.23M | (m) | 94.19% |
| 2018-06-30 | $5.61M | $5.93M | (m) | 94.59% |
| 2018-03-31 | $3.55M | $3.77M | (m) | 94.16% |
| 2017-12-31 | $3.29M | $3.46M | (m) | 95.14% |
| 2017-09-30 | $3.45M | $3.54M | (m) | 97.35% |
| 2017-06-30 | $3.25M | $3.35M | (m) | 97.02% |
| 2017-03-31 | $4.05M | $4.24M | (m) | 95.52% |
| 2016-12-31 | $5.57M | $5.92M | (m) | 93.96% |
| 2016-09-30 | $5.77M | $6.30M | (m) | 91.62% |
| 2016-06-30 | $6.21M | $7.11M | (m) | 87.31% |
| 2016-03-31 | $6.78M | $7.84M | (m) | 86.39% |
| 2015-12-31 | $5.93M | $7.04M | (m) | 84.27% |
| 2015-09-30 | $6.27M | $7.45M | (m) | 84.17% |
| 2015-06-30 | $5.36M | $6.34M | (m) | 84.55% |
| 2015-03-31 | $4.47M | $5.44M | (m) | 82.19% |
| 2014-12-31 | $4.41M | $5.24M | (m) | 84.04% |
| 2014-09-30 | $4.42M | $5.26M | (m) | 84.09% |
| 2014-06-30 | $3.97M | $4.78M | (m) | 83.02% |
| 2014-03-31 | $4.14M | $4.89M | (m) | 84.82% |
| 2013-12-31 | $3.64M | $4.43M | (m) | 82.12% |
| 2013-09-30 | $3.03M | $3.76M | (m) | 80.59% |
| 2013-06-30 | $3.36M | $4.05M | (m) | 82.91% |
| 2013-03-31 | $3.28M | $3.88M | (m) | 84.61% |
| 2012-12-31 | $3.48M | $3.92M | (m) | 88.91% |
| 2012-09-30 | (m) | (m) | (m) | (m) |
| 2012-06-30 | (m) | (m) | (m) | (m) |
| 2012-03-31 | (m) | $4.16M | (m) | (m) |
| 2011-12-31 | (m) | $4.35M | (m) | (m) |
| 2011-09-30 | (m) | (m) | (m) | (m) |
| 2011-06-30 | (m) | (m) | (m) | (m) |
| 2011-03-31 | (m) | (m) | (m) | (m) |
| 2010-12-31 | (m) | $3.68M | (m) | (m) |
| 2010-09-30 | (m) | (m) | (m) | (m) |
| 2010-06-30 | (m) | (m) | (m) | (m) |
| 2009-12-31 | (m) | $1.93M | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Aligos Therapeutics, Inc. (ALGS) | United States | $0.238B | -0.47 |
| SUTRO BIOPHARMA, INC. (STRO) | United States | $0.260B | -3.05 |
| Protalix BioTherapeutics, Inc. (PLX) | $0.221B | 9.87 | |
| ANAVEX LIFE SCIENCES CORP. (AVXL) | United States | $0.218B | -18.37 |
| Alector, Inc. (ALEC) | United States | $0.213B | -1.90 |
| Invivyd, Inc. (IVVD) | United States | $0.270B | -2.42 |
| PALISADE BIO, INC. (PALI) | United States | $0.275B | -11.41 |
| Compass Therapeutics, Inc. (CMPX) | United States | $0.204B | -5.35 |
| Lexeo Therapeutics, Inc. (LXEO) | United States | $0.278B | -4.19 |
| FATE THERAPEUTICS INC (FATE) | United States | $0.280B | -2.51 |